Periodontal Study On Imagenetix Compound 1-TDC Published In Journal Of Periodontology

Main Category: Dentistry
Also Included In: Infectious Diseases / Bacteria / Viruses;  Biology / Biochemistry;  Clinical Trials / Drug Trials
Article Date: 02 Jun 2007 - 0:00 PDT

email to a friend   printer friendly   opinions  

Imagenetix, Inc. (OTC Bulletin Board: IAGX), announced today the first scientific publication of a study that was conducted on its proprietary compound, 1-TDC, for the prevention of periodontal disease. The study which was conducted at Boston University was published in the April 26th issue of The Journal of Periodontology and is available online at http://www.joponline.org/loi/jop.

Commenting on the results of the study, Mr. William P. Spencer, President of Imagenetix said, "We are excited with the results of this study, which demonstrates the potential of our compound to become a major breakthrough for the prevention of periodontal disease." According to the American Academy of Periodontology over 50% of the adults over the age of 50 have periodontitis or periodontal diseases, which creates a potential multi-billion market for a product developed from our compound. We have recently submitted and received PRE-IND approval from the FDA to begin Safety Studies.

1-TDC is a proprietary blend of esterified fatty acids that inhibits many oral bacteria. Many of these bacteria have been identified with causing local and systemic inflammation. The purpose of the study was to investigate the effect of 1-TDC on Porphyromonas gingivalis (P. gingivalis) induced periodontitis. Boston University researchers have established the P. gingivalis-induced periodontitis model in rabbits and have extensively investigated the relationship of P.gingivalis infection to inflammation.

The study was performed under the direction of Hatice Hasturk, D.D.S., Ph.D.; Boston University, Department of Periodontology and Oral Biology. The study was conducted using a rabbit model established by Boston University researchers. Experimental periodontitis was induced in New Zealand white rabbits with silk sutures tied around the mandibular second pre-molars bilaterally and P.gingivalis applied topically. The test agent (1-TDC) was applied topically at concentrations of 1 mg/ml and 10 mg/ml three times per week for six weeks. After six weeks, 1-TDC showed a reduction of inflammation, cellular infiltration, connective tissue destruction and bone loss when compared to the placebo. "While both test concentrations exhibited benefit, 1-TDC given at 10 mg/ml offered the most significant improvement compared to placebo," stated Dr. Hasturk. "The opportunity for 1-TDC to reduce the likelihood for an individual for developing periodontal disease is exciting as there are limited options for treating periodontitis."

Mr. Spencer added, "The scientists at the Boston University, Goldman School of Dental Medicine have done an excellent job guiding us through the discovery process. This study forms the foundation for outlining the efficacy of 1-TDC for the prevention of periodontal disease. I am happy to report that Dr. Robert Hesslink, Director of Research & Development along with our clinical sciences staff continue to achieve research milestones in this novel form of treating periodontal diseases. We expect to report additional developments in the near future."

About Imagenetix

Based in San Diego, California, Imagenetix, (OTC Bulletin Board: IAGX) is an innovator of scientifically tested, natural-based, proprietary bioceutical products developed to enhance human health on a global basis. Imagenetix develops, formulates and private-labels propriety over-the-counter topical creams, skincare products and nutritional supplements to be marketed globally through multiple channels of distribution. In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners. Imagenetix is the creator of Inflame Away(TM)- Celadrin(R), which has been clinically tested to relieve osteoarthritis pain and significantly improve joint health. For more information, please visit, http://www.imagenetix.net.

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. These factors and others could cause operating results to vary significantly from those in prior periods and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company has filed and will periodically file with the Securities Exchange Commission.

Imagenetix, Inc.
http://www.imagenetix.net

• Additional
• References
• Citations